CLINICAL_TRIALS
trial_result
· 2019-03-18
Clinical Trial Update: Nintedanib (BIBF 1120) in Mesothelioma [Phase 2, Phase 3]
Summary
Clinical trial updates for nintedanib in mesothelioma (Phase 2/3) with terminated status and posted results.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Boehringer Ingelheim | Conditions: Mesothelioma | Phase 2, Phase 3 | Status: TERMINATED | Results posted: 2019-03-18